Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
| Income Statement [Abstract] | ||||
| REVENUES | ||||
| OPERATING EXPENSES | ||||
| Payroll and related expenses | 275,273 | 773,387 | 881,655 | 2,321,508 |
| Professional fees | 444,463 | 108,841 | 1,352,962 | 966,251 |
| General and administrative | 75,033 | 86,916 | 209,116 | 255,687 |
| Research and development expenses | 364,343 | 245,853 | 1,019,143 | 704,902 |
| Total Operating Expenses | 1,159,112 | 1,214,997 | 3,462,876 | 4,248,348 |
| LOSS FROM OPERATIONS | (1,159,112) | (1,214,997) | (3,462,876) | (4,248,348) |
| OTHER INCOME (EXPENSE) | ||||
| Financing costs including interest | (5,182) | (18,744) | (48,412) | (57,084) |
| Inducement interest | (397,928) | |||
| Total Other Expense, net | (5,182) | (18,744) | (446,340) | (57,084) |
| Loss from operations before income taxes | (1,164,294) | (1,233,741) | (3,909,216) | (4,305,432) |
| INCOME TAXES | ||||
| NET LOSS | (1,164,294) | (1,233,741) | (3,909,216) | (4,305,432) |
| PREFERRED STOCK | ||||
| Series A preferred contractual dividends | (7,200) | (7,200) | (21,600) | (20,420) |
| Series B preferred contractual dividends | (37,620) | (38,034) | (112,861) | (113,276) |
| Deemed dividends from Series A and B conversion price reduction | (40,461) | (305,541) | ||
| Deemed dividend on warrant modification | (282,309) | (41,225) | ||
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | $ (1,249,575) | $ (1,278,975) | $ (4,631,527) | $ (4,480,353) |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC | $ (0.36) | $ (0.75) | $ (1.60) | $ (2.66) |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: DILUTED | $ (0.36) | $ (0.75) | $ (1.60) | $ (2.66) |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC | 3,452,023 | 1,699,444 | 2,896,643 | 1,685,074 |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: DILUTED | 3,452,023 | 1,699,444 | 2,896,643 | 1,685,074 |
| X | ||||||||||
- Definition Deemed dividend on warrant modification No definition available.
|
| X | ||||||||||
- Definition Deemed dividends from series A and B conversion price reduction. No definition available.
|
| X | ||||||||||
- Definition Amount of amortization expense for deferred sales inducement cost from accrued interest on unamortized balance. No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition This element represents interest incurred for borrowed money which was used to produce goods or render services. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of preferred stock dividends and adjustments classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends). No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|